“Nasal polyps May Lead to lack of odor and Frequently patients need Operation to remove the polyps,” explained Sally Seymour, M.D.,” Director of the Department of Pulmonary, Allergy and Rheumatology Products at the FDA's Center for Drug Research and Evaluation. “Dupixent has a significant treatment alternative for patients whose sinus polyps aren't satisfactorily controlled by intranasal steroids. Additionally, it lowers the demand for rectal polyp operation and oral steroids”
Dupixent is distributed by means of injection. The efficiency and security of Dupixent Were created in 2 studies using 724 patients, 18 decades and older with chronic rhinosinusitis with nasal polyps that have been symptomatic despite carrying intranasal corticosteroids. Patients carrying Dupixent reported that an increased capacity to smell and also demanded less sinus polyp operation and oral steroids. If patients undergo worsening or new eye disorders, such as itching, redness, itching or visual adjustments, they should consult with their healthcare professional. Probably the most frequent side effects reported include injection site reactions in addition to eye and stomach swelling, which comprised swelling itching and swelling. Patients receiving Dupixent should prevent becoming vaccines that are live. Dupixent was originally accepted in 20 17 for individuals 12 and older With psoriasis which isn't controlled satisfactorily by topical remedies or When these remedies aren't highly recommended. As an addon care treatment for patients 12 decades and older . Moderate-to-severe eosinophilic asthma or oral corticosteroid-dependent asthma.
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.